Unlike MMRd ECs, uLMS is characterized by a low tumor mutational burden and a genomic landscape dominated by the inactivation of tumor suppressor genes such as TP53 and RB1, which may underlie its reported resistance to immunotherapy.[19] Moreover, the clinical benefit of systemic therapy in uLMS remains limited. Here, TP53 is linked to neoplasm.